Apogenix Announces that APG101 Meets Primary Endpoint in a Controlled Phase II Trial with Glioblastoma Patients
Apogenix Raises € 7.5 Million to Further Advance APG101 to Treat Glioblastoma and other Tumors
Apogenix Receives Additional € 2.3 Million BMBF Grant as Partner of the Biotech Cluster Rhine-Neckar
Apogenix Successfully Completes Patient Recruitment for Glioblastoma Phase II Trial with APG101
Apogenix Provides Update in the Ongoing Phase II Clinical Trial of APG101 to Treat Glioblastoma
Data Published in “Nature” Confirms Development of APG101 to Treat Cancer
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
Apogenix Receives Orphan Drug Designation for APG101 in the US and Positive Opinion on Orphan Product Designation in Europe
For further press releases please check our archive.
